Pharmacokinetics and biodistribution of radiolabelled idoxifene: Prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy
- 1 May 1995
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 22 (4) , 405-411
- https://doi.org/10.1016/0969-8051(94)00141-6
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.Journal of Clinical Oncology, 1994
- Synthesis of 4‐stannylated tamoxifen analogues; useful precursors to radiolabelled idoxifene and aziridinyl 4‐iodotamoxifenJournal of Labelled Compounds and Radiopharmaceuticals, 1994
- Hormone resistance, invasiveness, and metastatic potential in breast cancerBreast Cancer Research and Treatment, 1993
- Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituentJournal of Medicinal Chemistry, 1989
- TamoxifenDrugs, 1989
- Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancerBritish Journal of Cancer, 1988
- On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancerJournal of Molecular Medicine, 1987
- 99mTc-HMPAO as a tumour blood flow agentEuropean Journal of Nuclear Medicine and Molecular Imaging, 1987
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984
- Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significanceBreast Cancer Research and Treatment, 1982